ImmunityBio Shares Climb After European Commission Approves Bladder-Cancer Drug

Dow Jones03:00

By Katherine Hamilton

ImmunityBio shares rose after the company said it got conditional marketing authorization from European regulators for its drug to treat bladder cancer.

The stock climbed 32% to $7.94 on Wednesday. Shares have more than doubled over the past 12 months.

The immunotherapy company said Wednesday that the European Commission granted conditional marketing authorization for Anktiva in combination with Bacillus Calmette-Guerin for the treatment of adult patients with certain types of nonmuscle invasive bladder cancer.

With the authorization, Anktiva is now approved in 33 countries spanning four regulator jurisdictions. It was first approved by the U.S. Food and Drug Administration less than two years ago.

The authorization comes after patients treated with Anktiva demonstrated a 71% complete response rate in a recent clinical trial.

As part of the conditional authorization, ImmunityBio will follow up with trial participants and submit long-term safety and efficacy data to the European Medicines Agency, the company said.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

February 18, 2026 14:00 ET (19:00 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2612423995?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-19 03:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612423995","market":"nz","top_or_hot":-1,"title":"ImmunityBio Shares Climb After European Commission Approves Bladder-Cancer Drug","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  ImmunityBio shares rose after the company said it got conditional marketing authorization from European regulators for its drug to treat bladder cancer. \n</p>\n<p>\n  The stock climbed 32% to $7.94 on Wednesday. Shares have more than doubled over the past 12 months. \n</p>\n<p>\n  The immunotherapy company said Wednesday that the European Commission granted conditional marketing authorization for Anktiva in combination with Bacillus Calmette-Guerin for the treatment of adult patients with certain types of nonmuscle invasive bladder cancer. \n</p>\n<p>\n  With the authorization, Anktiva is now approved in 33 countries spanning four regulator jurisdictions. It was first approved by the U.S. Food and Drug Administration less than two years ago. \n</p>\n<p>\n  The authorization comes after patients treated with Anktiva demonstrated a 71% complete response rate in a recent clinical trial. \n</p>\n<p>\n  As part of the conditional authorization, ImmunityBio will follow up with trial participants and submit long-term safety and efficacy data to the European Medicines Agency, the company said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 18, 2026 14:00 ET (19:00 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ImmunityBio Shares Climb After European Commission Approves Bladder-Cancer Drug</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmunityBio Shares Climb After European Commission Approves Bladder-Cancer Drug\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-02-19 03:00</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Katherine Hamilton \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  ImmunityBio shares rose after the company said it got conditional marketing authorization from European regulators for its drug to treat bladder cancer. \n</p>\n<p>\n  The stock climbed 32% to $7.94 on Wednesday. Shares have more than doubled over the past 12 months. \n</p>\n<p>\n  The immunotherapy company said Wednesday that the European Commission granted conditional marketing authorization for Anktiva in combination with Bacillus Calmette-Guerin for the treatment of adult patients with certain types of nonmuscle invasive bladder cancer. \n</p>\n<p>\n  With the authorization, Anktiva is now approved in 33 countries spanning four regulator jurisdictions. It was first approved by the U.S. Food and Drug Administration less than two years ago. \n</p>\n<p>\n  The authorization comes after patients treated with Anktiva demonstrated a 71% complete response rate in a recent clinical trial. \n</p>\n<p>\n  As part of the conditional authorization, ImmunityBio will follow up with trial participants and submit long-term safety and efficacy data to the European Medicines Agency, the company said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 18, 2026 14:00 ET (19:00 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2612423995","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612423995","pubTimestamp":1771441200,"columns":[{"name":"Product Release","id":31,"label_key":"productRelease"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"ImmunityBio shares rose after the company said it got conditional marketing authorization from European regulators for its drug to treat bladder cancer.The stock climbed 32% to $7.94 on Wednesday. Shares have more than doubled over the past 12 months.The immunotherapy company said Wednesday that the European Commission granted conditional marketing authorization for Anktiva in combination with Bacillus Calmette-Guerin for the treatment of adult patients with certain types of nonmuscle invasive bladder cancer.With the authorization, Anktiva is now approved in 33 countries spanning four regulator jurisdictions. It was first approved by the U.S. Food and Drug Administration less than two years ago.The authorization comes after patients treated with Anktiva demonstrated a 71% complete response rate in a recent clinical trial.As part of the conditional authorization, ImmunityBio will follow up with trial participants and submit long-term safety and efficacy data to the European Medicines Ag","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","IBRX":"ImmunityBio, Inc."},"translate_title":"欧盟委员会批准膀胱癌药物后ImmunityBio股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBRX":0.9},"content_text":"By Katherine Hamilton \n\n\n \n\n\n  ImmunityBio shares rose after the company said it got conditional marketing authorization from European regulators for its drug to treat bladder cancer. \n\n\n  The stock climbed 32% to $7.94 on Wednesday. Shares have more than doubled over the past 12 months. \n\n\n  The immunotherapy company said Wednesday that the European Commission granted conditional marketing authorization for Anktiva in combination with Bacillus Calmette-Guerin for the treatment of adult patients with certain types of nonmuscle invasive bladder cancer. \n\n\n  With the authorization, Anktiva is now approved in 33 countries spanning four regulator jurisdictions. It was first approved by the U.S. Food and Drug Administration less than two years ago. \n\n\n  The authorization comes after patients treated with Anktiva demonstrated a 71% complete response rate in a recent clinical trial. \n\n\n  As part of the conditional authorization, ImmunityBio will follow up with trial participants and submit long-term safety and efficacy data to the European Medicines Agency, the company said. \n\n\n \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 18, 2026 14:00 ET (19:00 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2612423995","isCrawlerRequest":true}